General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Khosla Ventures Acquisition Co. in Business Combination with Valo Health

June 9, 2021
Members of the firm’s Emerging Companies, M&A, and Capital Markets Practices are advising the SPAC.

Valo Health, LLC (Valo), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (KVAC) (NASDAQ: KVSA), a special purpose acquisition company founded by affiliates of Khosla Ventures, LLC, have announced that they have entered into a definitive merger agreement. The transaction values the combined company at a pro forma market value of approximately US$2.8 billion.

Latham & Watkins LLP represents Khosla Ventures Acquisition Co. in the transaction with a corporate deal team led by Bay Area partners Jim Morrone, Luke Bergstrom, and Brian Paulson, with associates Lauren Lefcoe and Trevor Bossi. Advice was also provided on intellectual property and data privacy and security matters by Bay Area partner Michelle Gross, with associate Ryan Sanders; on tax matters by Bay Area partner Kirt Switzer, with associate Jacob Meninga; on benefits and compensation matters by Bay Area partner Julie Crisp and Los Angeles counsel Aryeh Zuber, with associate Rachel Narowski; on healthcare regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with associate Kiera Murphy; and on antitrust matters by Washington, D.C. counsel Patrick English.